Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zytiga

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

- PMLiVE

Pfizer’s Talzenna combination shows promise in phase 3 prostate cancer study

10-20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

- PMLiVE

AstraZeneca progresses application for $360m Ireland manufacturing site

The investment is expected to create around 100 highly skilled jobs

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

- PMLiVE

World Cancer Day: encouraging men to put their health first

A three-year campaign, running from 2022 to 2024, focuses on ‘Closing the Care Gap’

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

- PMLiVE

AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system

More than 43,000 people are diagnosed with lung cancer every year in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links